CAR T Cell Toxicity: Current Management and Future Directions
Abstract. By late 2018, 2 chimeric antigen receptor T (CAR T) cell products have been approved by US and European regulatory authorities. Tisagenlecleucel (Kymriah, Novartis) is indicated in the treatment of patients up to 25 years of age with B-cell acute lymphoblastic leukemia (ALL) that is refrac...
Main Authors: | Lucrecia Yáñez, Miriam Sánchez-Escamilla, Miguel-Angel Perales |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-04-01
|
Series: | HemaSphere |
Online Access: | http://journals.lww.com/10.1097/HS9.0000000000000186 |
Similar Items
-
Toxicity and management in CAR T-cell therapy
by: Challice L Bonifant, et al.
Published: (2016-01-01) -
Current status and future challenges of CAR-T cell therapy for osteosarcoma
by: Shizhe Li, et al.
Published: (2023-12-01) -
Adverse Cardiac Effects of CAR T-Cell Therapy: Characteristics, Surveillance, Management, and Future Research Directions
by: Prarthana J. Dalal MD PhD, et al.
Published: (2022-10-01) -
CAR-NK cells for cancer immunotherapy: recent advances and future directions
by: Tianye Li, et al.
Published: (2024-02-01) -
CAR T-Cells in Acute Lymphoblastic Leukemia: Current Status and Future Prospects
by: Abdulrahman H. Almaeen, et al.
Published: (2023-10-01)